---
title: "Mucosal clonal CAR+ T cell expansion drives enterocolitis after BCMA CAR-T (cilta-cel)"
id: "nature-1-expansion-and-cytotoxicity-of-mucosal-car-t-cells-in-enterocolitis-associated"
canonical_url: "https://medichelpline.com/clinical-feed/nature-1-expansion-and-cytotoxicity-of-mucosal-car-t-cells-in-enterocolitis-associated"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04731-w"
published_at: "2026-11-19T10:38:08.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Mucosal clonal CAR+ T cell expansion drives enterocolitis after BCMA CAR-T (cilta-cel)
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-1-expansion-and-cytotoxicity-of-mucosal-car-t-cells-in-enterocolitis-associated
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04731-w)
- **Published At:** 2026-11-19T10:38:08.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators analyzed cases of severe post–CAR T cell enterocolitis linked to **cilta-cel** in patients treated for multiple myeloma. The cohort described nine cases with mucosal infiltration. - The source reported an incidence of 5.1% at a 6-month landmark among 158 patients at a single center and a global incidence estimate of 5.7%. - All reported cases showed monoclonal or oligoclonal **CAR+** T cell populations by vector integration analysis, flow cytometry and T cell receptor sequencing. - Peripheral blood from affected patients contained roughly 100-fold higher persistent **CAR+** T cell levels than in patients without enterocolitis, according to the authors. - RNA sequencing of mucosal infiltrates identified elevated cytotoxic and inflammatory transcriptional programs in **CAR+** cells relative to controls. - Vector integration events clustered in introns of highly expressed genes; the authors did not find evidence that vector-mediated mutagenesis explained the phenotype. - Candidate driver mutations were described as sparse and heterogeneous; this pattern differentiated IEC-EC from reported post-CAR peripheral T cell lymphomas. - Pathology was dominated by clonal **CAR+** cytotoxic T cell infiltration, with a duodenum-predominant distribution in the gastrointestinal tract. - The report cites prior case series and regulatory action: an FDA labeling change added a boxed warning for immune effector cell-associated enterocolitis following **cilta-cel**. - The study team observed that IEC-EC represents a distinct, clonal lymphoproliferative disorder rather than a typical inflammatory diarrheal syndrome; unanswered questions include precise drivers of clonal expansion and mechanisms linking integration sites to tissue tropism.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04731-w#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04731-w) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article Expansion and cytotoxicity of mucosal CAR+ T cells in enterocolitis associated with BCMA CAR-T cell therapy [ Download PDF ](https://www.nature.com/articles/s41591-026-04731-w.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04731-w.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 19 November 2026 # Expansion and cytotoxicity of mucosal CAR+ T cells in enterocolitis associated with BCMA CAR-T cell therapy * [Tania P. Sainz](https://www.nature.com/articles/s41591-026-04731-w#auth-Tania_P_-Sainz-Aff1-Aff2) [ORCID: orcid.org/0009-0002-1476-5680](https://orcid.org/0009-0002-1476-5680)[1](https://www.nature.com/articles/s41591-026-04731-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04731-w#Aff2) [na1](https://www.nature.com/articles/s41591-026-04731-w#na1), * [Sharlene Dong](https://www.nature.com/articles/s41591-026-04731-w#auth-Sharlene-Dong-Aff3)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3) [na1](https://www.nature.com/articles/s41591-026-04731-w#na1), * [Aniruddha Mundhada](https://www.nature.com/articles/s41591-026-04731-w#auth-Aniruddha-Mundhada-Aff3) [ORCID: orcid.org/0000-0001-6420-4932](https://orcid.org/0000-0001-6420-4932)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3) [na1](https://www.nature.com/articles/s41591-026-04731-w#na1), * [Wei Wang](https://www.nature.com/articles/s41591-026-04731-w#auth-Wei-Wang-Aff1) [ORCID: orcid.org/0000-0001-6821-4556](https://orcid.org/0000-0001-6821-4556)[1](https://www.nature.com/articles/s41591-026-04731-w#Aff1), * [Hector Garcia Pleitez](https://www.nature.com/articles/s41591-026-04731-w#auth-Hector_Garcia-Pleitez-Aff3) [ORCID: orcid.org/0009-0007-9711-7473](https://orcid.org/0009-0007-9711-7473)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Carla Villela](https://www.nature.com/articles/s41591-026-04731-w#auth-Carla-Villela-Aff3)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Jared Henderson](https://www.nature.com/articles/s41591-026-04731-w#auth-Jared-Henderson-Aff3)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Amy A. Ayers](https://www.nature.com/articles/s41591-026-04731-w#auth-Amy_A_-Ayers-Aff3)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Karmila Murphy](https://www.nature.com/articles/s41591-026-04731-w#auth-Karmila-Murphy-Aff3)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Francisco Cortina](https://www.nature.com/articles/s41591-026-04731-w#auth-Francisco-Cortina-Aff4)[4](https://www.nature.com/articles/s41591-026-04731-w#Aff4), * [Bita Sahaf](https://www.nature.com/articles/s41591-026-04731-w#auth-Bita-Sahaf-Aff4)[4](https://www.nature.com/articles/s41591-026-04731-w#Aff4), * [Snehit Prabhu](https://www.nature.com/articles/s41591-026-04731-w#auth-Snehit-Prabhu-Aff4)[4](https://www.nature.com/articles/s41591-026-04731-w#Aff4), * [Partow Kebriaei](https://www.nature.com/articles/s41591-026-04731-w#auth-Partow-Kebriaei-Aff5)[5](https://www.nature.com/articles/s41591-026-04731-w#Aff5), * [Wei-Lien Wang](https://www.nature.com/articles/s41591-026-04731-w#auth-Wei_Lien-Wang-Aff6) [ORCID: orcid.org/0000-0001-8809-4424](https://orcid.org/0000-0001-8809-4424)[6](https://www.nature.com/articles/s41591-026-04731-w#Aff6), * [Christopher D. Pacheco](https://www.nature.com/articles/s41591-026-04731-w#auth-Christopher_D_-Pacheco-Aff7)[7](https://www.nature.com/articles/s41591-026-04731-w#Aff7), * [Xuehong Gui](https://www.nature.com/articles/s41591-026-04731-w#auth-Xuehong-Gui-Aff7)[7](https://www.nature.com/articles/s41591-026-04731-w#Aff7), * [Christopher R. Flowers](https://www.nature.com/articles/s41591-026-04731-w#auth-Christopher_R_-Flowers-Aff3)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Sattva S. Neelapu](https://www.nature.com/articles/s41591-026-04731-w#auth-Sattva_S_-Neelapu-Aff3) [ORCID: orcid.org/0000-0003-1045-4914](https://orcid.org/0000-0003-1045-4914)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Paolo Strati](https://www.nature.com/articles/s41591-026-04731-w#auth-Paolo-Strati-Aff3) [ORCID: orcid.org/0000-0002-7445-1459](https://orcid.org/0000-0002-7445-1459)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Mahmoud R. Gaballa](https://www.nature.com/articles/s41591-026-04731-w#auth-Mahmoud_R_-Gaballa-Aff3) [ORCID: orcid.org/0000-0002-3928-6590](https://orcid.org/0000-0002-3928-6590)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Oren Pasvolsky](https://www.nature.com/articles/s41591-026-04731-w#auth-Oren-Pasvolsky-Aff3)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Robert Orlowski](https://www.nature.com/articles/s41591-026-04731-w#auth-Robert-Orlowski-Aff3) [ORCID: orcid.org/0000-0002-5723-4129](https://orcid.org/0000-0002-5723-4129)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Keyur Patel](https://www.nature.com/articles/s41591-026-04731-w#auth-Keyur-Patel-Aff1)[1](https://www.nature.com/articles/s41591-026-04731-w#Aff1), * [Surbhi Sidana](https://www.nature.com/articles/s41591-026-04731-w#auth-Surbhi-Sidana-Aff4) [ORCID: orcid.org/0000-0003-3288-7614](https://orcid.org/0000-0003-3288-7614)[4](https://www.nature.com/articles/s41591-026-04731-w#Aff4), * [Crystal Mackall](https://www.nature.com/articles/s41591-026-04731-w#auth-Crystal-Mackall-Aff4) [ORCID: orcid.org/0000-0001-6323-4304](https://orcid.org/0000-0001-6323-4304)[4](https://www.nature.com/articles/s41591-026-04731-w#Aff4), * [David B. Miklos](https://www.nature.com/articles/s41591-026-04731-w#auth-David_B_-Miklos-Aff4) [ORCID: orcid.org/0000-0003-0717-4305](https://orcid.org/0000-0003-0717-4305)[4](https://www.nature.com/articles/s41591-026-04731-w#Aff4), * [Yinghong Wang](https://www.nature.com/articles/s41591-026-04731-w#auth-Yinghong-Wang-Aff8) [ORCID: orcid.org/0000-0002-5148-6130](https://orcid.org/0000-0002-5148-6130)[8](https://www.nature.com/articles/s41591-026-04731-w#Aff8), * [David M. Richards](https://www.nature.com/articles/s41591-026-04731-w#auth-David_M_-Richards-Aff8) [ORCID: orcid.org/0000-0002-4996-6063](https://orcid.org/0000-0002-4996-6063)[8](https://www.nature.com/articles/s41591-026-04731-w#Aff8), * [Sairah Ahmed](https://www.nature.com/articles/s41591-026-04731-w#auth-Sairah-Ahmed-Aff3) [ORCID: orcid.org/0000-0001-7302-8299](https://orcid.org/0000-0001-7302-8299)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Michael R. Green](https://www.nature.com/articles/s41591-026-04731-w#auth-Michael_R_-Green-Aff3-Aff7) [ORCID: orcid.org/0000-0001-6309-9472](https://orcid.org/0000-0001-6309-9472)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3),[7](https://www.nature.com/articles/s41591-026-04731-w#Aff7), * [Lekha Mikkilineni](https://www.nature.com/articles/s41591-026-04731-w#auth-Lekha-Mikkilineni-Aff4) [ORCID: orcid.org/0009-0003-7698-5934](https://orcid.org/0009-0003-7698-5934)[4](https://www.nature.com/articles/s41591-026-04731-w#Aff4), * [Sa A. Wang](https://www.nature.com/articles/s41591-026-04731-w#auth-Sa_A_-Wang-Aff1) [ORCID: orcid.org/0000-0001-9385-9911](https://orcid.org/0000-0001-9385-9911)[1](https://www.nature.com/articles/s41591-026-04731-w#Aff1), * [Ziyi Li](https://www.nature.com/articles/s41591-026-04731-w#auth-Ziyi-Li-Aff9) [ORCID: orcid.org/0000-0001-8359-0533](https://orcid.org/0000-0001-8359-0533)[9](https://www.nature.com/articles/s41591-026-04731-w#Aff9), * [Swami P. Iyer](https://www.nature.com/articles/s41591-026-04731-w#auth-Swami_P_-Iyer-Aff3)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3), * [Krina K. Patel](https://www.nature.com/articles/s41591-026-04731-w#auth-Krina_K_-Patel-Aff3) [ORCID: orcid.org/0000-0002-8894-027X](https://orcid.org/0000-0002-8894-027X)[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3) [na2](https://www.nature.com/articles/s41591-026-04731-w#na2), * [Francisco Vega](https://www.nature.com/articles/s41591-026-04731-w#auth-Francisco-Vega-Aff1) [ORCID: orcid.org/0000-0001-5956-452X](https://orcid.org/0000-0001-5956-452X)[1](https://www.nature.com/articles/s41591-026-04731-w#Aff1) [na2](https://www.nature.com/articles/s41591-026-04731-w#na2) & * … * [Mark P. Hamilton](https://www.nature.com/articles/s41591-026-04731-w#auth-Mark_P_-Hamilton-Aff2-Aff3) [ORCID: orcid.org/0000-0002-3732-8910](https://orcid.org/0000-0002-3732-8910)[2](https://www.nature.com/articles/s41591-026-04731-w#Aff2),[3](https://www.nature.com/articles/s41591-026-04731-w#Aff3) [na2](https://www.nature.com/articles/s41591-026-04731-w#na2) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04731-w#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract Ciltacabtagene autoleucel (cilta-cel) is a B cell maturation-antigen-targeting chimeric antigen receptor (CAR) T cell product approved for relapsed/refractory multiple myeloma treatment. Previously reported cases of post-cilta-cel immune effector cell enterocolitis (IEC-EC) have been described as a severe diarrhea associated with clonal CAR T cell populations. Here we report nine cases of cilta-cel-associated IEC-EC with CAR T cell-positive (CAR+) infiltration in 158 cilta-cel-treated patients at MD Anderson Cancer Center (incidence of 5.1% at a 6-month landmark and 5.7% globally). Cilta-cel infiltration was the primary cause of IEC-EC, and all cases demonstrated monoclonal or oligoclonal T cell populations as measured by vector integration analysis, flow cytometry and T cell receptor sequencing. Patients with IEC-EC had 100-fold more CAR T cell persistence in the peripheral blood than patients without IEC-EC. RNA sequencing analysis revealed increased cytotoxic and inflammatory programs associated with the CAR+ infiltrates relative to controls. Clonal vector integration occurred in introns of highly expressed genes without evidence of vector-mediated mutagenesis. Candidate driver mutations were sparse and heterogeneous, distinguishing IEC-EC from peripheral T cell lymphoma following CAR T cell therapy. In sum, we find that IEC-EC pathology represents a distinct, duodenum-predominant, clonal lymphoproliferative disorder characterized by the infiltration of clonal CAR+ cytotoxic T cells into the gastrointestinal tract. ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Haematological diseases](https://www.nature.com/subjects/haematological-diseases) * [Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies](https://www.nature.com/subjects/chimeric-antigen-receptor-t-cell-therapy-in-hematological-malignancies) ## Main Chimeric antigen receptor (CAR) T cell therapy has led to deep and durable responses for patients with multiple myeloma (MM)[1](https://www.nature.com/articles/s41591-026-04731-w#ref-CR1 "Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma \(CARTITUDE-1\): a phase 1b/2 open-label study. Lancet 398, 314–324 \(2021\)."),[2](https://www.nature.com/articles/s41591-026-04731-w#ref-CR2 "San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2303379 \(2023\)."). Ciltacabtagene autoleucel (cilta-cel) is a B cell maturation antigen (BCMA)-directed CAR T cell product currently approved for relapsed/refractory MM treatment. Although cilta-cel is generally well tolerated, it may cause common CAR-related toxicities such as cytokine release syndrome (CRS) and immune-effector-cell-associated neurotoxicity syndrome (ICANS). In addition to these common post-CAR complications, cilta-cel can cause unique non-ICANS neurologic symptoms, including a hypokinetic syndrome that mimics Parkinson bradykinesia[3](https://www.nature.com/articles/s41591-026-04731-w#ref-CR3 "Van Oekelen, O. et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat. Med. 27, 2099–2103 \(2021\)."),[4](https://www.nature.com/articles/s41591-026-04731-w#ref-CR4 "Graham, C. E. et al. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 26, e203–e213 \(2025\)."). Reports of CAR T cell positive (CAR+) T cell neoplasms in patients receiving CAR-T cell therapy have emerged[5](https://www.nature.com/articles/s41591-026-04731-w#ref-CR5 "Hosoya, H., et al. Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine. Blood https://doi.org/10.1182/blood.2025031423 \(2025\)."),[6](https://www.nature.com/articles/s41591-026-04731-w#ref-CR6 "Blumenberg, V. et al. Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. Blood https://doi.org/10.1182/blood.2025032347 \(2026\)."),[7](https://www.nature.com/articles/s41591-026-04731-w#ref-CR7 "Braun, T. et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat. Med. 31, 1145–1153 \(2025\)."),[8](https://www.nature.com/articles/s41591-026-04731-w#ref-CR8 "Perica, K. et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N. Engl. J. Med. 392, 577–583 \(2025\)."),[9](https://www.nature.com/articles/s41591-026-04731-w#ref-CR9 "Ozdemirli, M. et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N. Engl. J. Med. 390, 2074–2082 \(2024\)."),[10](https://www.nature.com/articles/s41591-026-04731-w#ref-CR10 "Harrison, S. J. et al. CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma. N. Engl. J. Med. 392, 677–685 \(2025\)."), resulting in a boxed warning regarding risk of secondary malignancy after CAR T cell therapies[11](https://www.nature.com/articles/s41591-026-04731-w#ref-CR11 "Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. https://doi.org/10.1056/NEJMp2400209 \(2024\)."),[12](https://www.nature.com/articles/s41591-026-04731-w#ref-CR12 "FDA approves labeling changes that include a boxed warning for immune effector cell-associated enterocolitis following treatment with ciltacabtagene autoleucel \(CARVYKTI, Janssen Biotech, Inc.\). \(FDA, 2025\)."). Despite these concerns, CAR+ neoplasms are still extremely rare. One emerging form of possible CAR+ T cell malignancy described by multiple recent reports is post-CAR peripheral T cell lymphomas (PTCLs)[9](https://www.nature.com/articles/s41591-026-04731-w#ref-CR9 "Ozdemirli, M. et al.
## Related Clinical Research

- [VINCIT preprint: biomaterial niche for spatially controlled in vivo CAR T engineering](https://medichelpline.com/clinical-feed/biorxiv-15-vincit-a-virus-incorporated-biomaterial-niche-enables-spatially-controlled-in.md)
- [Single-cell atlas defines molecular subtypes and microenvironment changes in cutaneous T cell lymp](https://medichelpline.com/clinical-feed/biorxiv-4-large-scale-integrated-single-cell-analysis-reveals-molecular-subtypes-and.md)
- [Forbion secures $2.6 billion in its largest fundraise to date](https://medichelpline.com/clinical-feed/stat-news-1-stat-forbion-raises-2-6-billion-its-largest-fundraise-to-date.md)
- [LCatlas: Point-of-Care Prediction Tool for Immunotherapy Response in NSCLC](https://medichelpline.com/clinical-feed/medrxiv-19-lcatlas-a-point-of-care-tool-for-predicting-immunotherapy-outcomes-in-non-small.md)
- [Context-dependent roles of DJ-1 (PARK7) in oxidative-stress diseases: neuroprotection versus tumor](https://medichelpline.com/clinical-feed/pubmed-43059404.md) (DOI: 10.3892/mmr.2026.14076)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.